Day 1 - Tuesday, November 18, 2025Tuesday, 18 November 2025 - ET (Eastern Time, GMT-05:00)

Before diving into deeper, supplemental sessions, take this opportunity for a broader level set. Gain insight into current policies and pending changes to understand how the copay industry will be affected in 2025, and beyond, and learn the steps that your organization should be taking to prepare and adapt accordingly.

With increasing cost pressures and evolving payer strategies, manufacturers must continually adapt their copay programs. This session provides insights into innovative program structures, split adjudication, specialty pharmacy coordination and compliance best practices to ensure long-term program success.

In this session, attendees gain a comprehensive understanding of how analyzing copay data can reveal critical patterns and trends that impact patient behavior and treatment adherence. Learn about practical examples and case studies demonstrating how leveraging these insights can lead to more personalized patient experiences, ultimately enhancing satisfaction and adherence to prescribed treatments. Key takeaways include:

• Understanding the role of copay data in identifying barriers to treatment adherence

• Strategies for utilizing copay insights to design patient-centric interventions

• Real-world examples of improved patient outcomes through data-driven approaches

• Best practices for integrating copay data analysis into existing healthcare frameworks

Despite the rapid evolution of payer strategies and access challenges, the capabilities and solutions within patient affordability have remained largely stagnant. For pharmaceutical manufacturers, this lack of progress comes at a time when barriers such as payer interference, program abuse and patient access issues are reaching new heights. This session will explore how renewed focus on patient affordability innovation is driving meaningful changes across the industry. Attendees will gain valuable insights into what is now possible, and how copay models are evolving – combining expertise, practicality, technical innovation and common-sense to address today’s most pressing affordability challenges and improve the patient experience. Attendees will learn:

• Why legacy maximizer programs remain stuck in mitigation, the evolving landscape of fraud and abuse in copay programs – and the unexpected culprits to watch

• How an innovative business rule hierarchy is rapidly expanding the capabilities of copay support program design

• The combined role of fintech, EDI, and modern HCP workflow insights are driving efficiency across medical benefit copay programs

• How a practical approach to copay program transition is finally allowing manufacturers the flexibility to optimize their patient access strategy

In an increasingly consumer-driven healthcare environment, patients are navigating complex financial decisions that go well beyond traditional models. This session explores how pharmaceutical manufacturers can design affordability strategies that are tailored to both therapeutic area characteristics and patient behavior in a fragmented access landscape. From specialty therapies requiring high-touch support to retail products competing in cash-pay markets, success depends on understanding how patients evaluate cost, convenience, and perceived value.

• How consumer behavior and affordability needs vary across patient segments

• Designing programs that address varying patient segments including insured and uninsured patient segments

• Analyze the GTN implications of key patient support components

• The role of price transparency, pharmacy choice, and digital tools in patient decision-making

• Case studies of customized affordability strategies 

Alongside patient trends, copay program data can also provide valuable insights into payer dynamics, formulary positioning and patient affordability trends. This session explores how manufacturers can effectively collect, analyze and utilize data to refine their market access strategies and enhance their copay programs.

With reimbursement spend under scrutiny and pricing pressures intensifying, manufacturers must rethink their GTN strategy to balance profitability and patient access with long-term program sustainability.

• Discover tactical approaches to mitigate spend while maintaining patient affordability

• Benchmark best practices for contract negotiation

• Run through commercial vs. cash-paying GTN considerations

• Learn the different components that make up GTN such as, rebates, PBM fees, 340B pricing and accumulators, and their role in shaping net revenue

CSR Activity

As your team gears up for an exciting product launch, it is essential that you have the right structure in place to ensure program success. Run through the timeline leading up to launch to guarantee that you have the right answers to all the following questions –

• How do you create a comprehensive launch, in which all internal stakeholders are educated and aligned?

• What are the key metrics to identify, and key conversations that should be had at, 18 months, 12 months, 6 months out, etc.?

• How do you determine if your current copay amount is sufficient for a new indication? If you were to change the amount, what are the organizational implications?

• How do you identify opportunities and gaps within your program to optimize patient outcome?

Once your copay program has been implemented, teams must remain agile to ensure that the program remains a seamless extension of the organization. Run through the timeline post launch to guarantee that you have the right answers to all the following questions –

• How do you make patient processes more effective?

• What does the bifurcation process look like from an operational perspective?

• What are best practices in collaborating with your specialty pharmacy, vendor partner and other external stakeholders?

• What are common barriers that manufacturers should expect throughout the program lifecycle?